Show simple item record

dc.contributor.authorSiddiqi, N
dc.contributor.authorNeil, C
dc.contributor.authorBruce, M
dc.contributor.authorMacLennan, G
dc.contributor.authorCotton, S
dc.contributor.authorPapadopoulou, S
dc.contributor.authorFeelisch, M
dc.contributor.authorBunce, N
dc.contributor.authorLim, PO
dc.contributor.authorHildick-Smith, D
dc.contributor.authorHorowitz, J
dc.contributor.authorMadhani, M
dc.contributor.authorBoon, N
dc.contributor.authorDawson, D
dc.contributor.authorKaski, JC
dc.contributor.authorFrenneaux, M
dc.date.accessioned2021-02-04T00:04:21Z
dc.date.available2021-02-04T00:04:21Z
dc.date.issued2014-05-01
dc.identifierpii: ehu096
dc.identifier.citationSiddiqi, N., Neil, C., Bruce, M., MacLennan, G., Cotton, S., Papadopoulou, S., Feelisch, M., Bunce, N., Lim, P. O., Hildick-Smith, D., Horowitz, J., Madhani, M., Boon, N., Dawson, D., Kaski, J. C. & Frenneaux, M. (2014). Intravenous sodiumnitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). EUROPEAN HEART JOURNAL, 35 (19), pp.1255-+. https://doi.org/10.1093/eurheartj/ehu096.
dc.identifier.issn0195-668X
dc.identifier.urihttp://hdl.handle.net/11343/259024
dc.description.abstractAIM: Despite prompt revascularization of acute myocardial infarction (AMI), substantial myocardial injury may occur, in part a consequence of ischaemia reperfusion injury (IRI). There has been considerable interest in therapies that may reduce IRI. In experimental models of AMI, sodium nitrite substantially reduces IRI. In this double-blind randomized placebo controlled parallel-group trial, we investigated the effects of sodium nitrite administered immediately prior to reperfusion in patients with acute ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS: A total of 229 patients presenting with acute STEMI were randomized to receive either an i.v. infusion of 70 μmol sodium nitrite (n = 118) or matching placebo (n = 111) over 5 min immediately before primary percutaneous intervention (PPCI). Patients underwent cardiac magnetic resonance imaging (CMR) at 6-8 days and at 6 months and serial blood sampling was performed over 72 h for the measurement of plasma creatine kinase (CK) and Troponin I. Myocardial infarct size (extent of late gadolinium enhancement at 6-8 days by CMR-the primary endpoint) did not differ between nitrite and placebo groups after adjustment for area at risk, diabetes status, and centre (effect size -0.7% 95% CI: -2.2%, +0.7%; P = 0.34). There were no significant differences in any of the secondary endpoints, including plasma troponin I and CK area under the curve, left ventricular volumes (LV), and ejection fraction (EF) measured at 6-8 days and at 6 months and final infarct size (FIS) measured at 6 months. CONCLUSIONS: Sodium nitrite administered intravenously immediately prior to reperfusion in patients with acute STEMI does not reduce infarct size.
dc.languageEnglish
dc.publisherOXFORD UNIV PRESS
dc.titleIntravenous sodiumnitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI)
dc.typeJournal Article
dc.identifier.doi10.1093/eurheartj/ehu096
melbourne.affiliation.departmentMedicine and Radiology
melbourne.affiliation.facultyCollected Works
melbourne.source.titleEuropean Heart Journal
melbourne.source.volume35
melbourne.source.issue19
melbourne.source.pages1255-+
dc.rights.licenseCC BY-NC
melbourne.elementsid1198007
melbourne.contributor.authorNeil, Christopher
dc.identifier.eissn1522-9645
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record